Latest Earnings Results: Q2 '26
Estimated EPS
-$2.35
Reported EPS
-$1.99
Surprise
+15.5%
Estimated Rev
$360.3M
Reported Rev
$364.3M
Surprise
+1.11%
• Reported GAAP EPS of -$1.99 down -4.74% YoY • Reported revenue of $364.25M up 71.17% YoY
Bullish Takeaway
Madrigal Pharmaceuticals delivered strong revenue growth and doubled its patient base for Rezdiffra, supported by continued physician adoption and a strengthened intellectual property portfolio for its core MASH treatment.
Bearish Takeaway
Madrigal Pharmaceuticals reported an increased net loss and higher operating expenses during the second quarter of 2026, while the company remains subject to inherent clinical trial and regulatory development risks.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.91 | -- | -- | N/A |
Q2 '26 | -$2.35 | -$1.99 | 15.50% | BEAT |
Q1 '26 | -$4.23 | -$3.25 | 23.16% | BEAT |
Q4 '25 | -$1.00 | -$2.57 | -158.00% | MISSED |
Q3 '25 | -$2.29 | -$5.08 | -122.31% | MISSED |